OpGen, Inc. (OPGN) |
|
1.4929 0.098 (7.02%)
|
03-24 11:42 |
|
Open: |
1.4 |
Pre. Close: |
1.395 |
|
High:
|
1.54 |
Low:
|
1.38 |
|
Volume:
|
373,182 |
Market Cap:
|
5(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 10:46:14 AM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 1.86 One year: 2.18 |
| Support: |
Support1: 1.18 Support2: 0.93 |
| Resistance: |
Resistance1: 1.6 Resistance2: 1.86 |
| Pivot: |
1.27 |
| Moving Average: |
MA(5): 1.44 MA(20): 1.22
MA(100): 2.4  MA(250): 6.64 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 72.6 %D(3): 72.8 |
| RSI: |
RSI(14): 55.6 |
| 52-week: |
High: 16.39 Low: 0.48 |
| Average Vol(K): |
3-Month: 466 (K) 10-Days: 744 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ OPGN ] has closed below upper band by 22.1%. Bollinger Bands are 39% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.47 - 1.48 |
1.48 - 1.49 |
|
Low:
|
1.35 - 1.36 |
1.36 - 1.37 |
|
Close:
|
1.39 - 1.4 |
1.4 - 1.41 |
|
Company Description |
|
OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland. |
Headline News |
Wed, 22 Mar 2023
Should You Buy OpGen Inc (OPGN) Stock After it Has Risen 0.76% in a Week? - InvestorsObserver
Wed, 22 Mar 2023
OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2022 on March 29th at 4:30 p.m. Eastern Time - Yahoo Finance
Tue, 14 Mar 2023
Will OpGen Inc (OPGN) Underperform the Rest of the Stocks in the Healthcare Sector? - InvestorsObserver
Thu, 09 Mar 2023
Should You Hold OpGen Inc (OPGN) Stock Thursday? - InvestorsObserver
Fri, 17 Feb 2023
OpGen Announces Exercise of All Prefunded Warrants - OpGen, Inc.
Wed, 18 Jan 2023
OpGen Provides Preliminary Unaudited Revenue for FY 2022 and ... - OpGen, Inc.
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Diagnostics & Research |
| Shares Out. |
3 (M) |
| Shares Float |
3 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
1.9 (%) |
|
Shares Short
|
146 (K) |
|
Shares Short P.Month
|
159 (K) |
Stock Financials |
|
EPS
|
-24.82 |
|
EPS Est Next Qtl
|
-0.06 |
|
EPS Est This Year
|
-0.42 |
|
EPS Est Next Year
|
-0.16 |
|
Book Value (p.s.)
|
5.76 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-708 |
|
Return on Assets (ttm)
|
-30.8 |
|
Return on Equity (ttm)
|
-142.1 |
|
Qtrly Rev. Growth
|
-63.8 |
|
Gross Profit (p.s.)
|
-2.94 |
|
Sales Per Share
|
1.02 |
|
EBITDA (p.s.)
|
-6.69 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-20 (M) |
|
Levered Free Cash Flow
|
-14 (M) |
Stock Valuations |
|
PE Ratio
|
-0.06 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.25 |
|
Price to Sales
|
1.43 |
|
Price to Cash Flow
|
-0.24 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2019-08-28 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
